Select your local Sysmex website

JAPAN

AMERICAS

EMEA

ASIA PACIFIC

GLOBAL HEADQUARTERS (JAPAN)

REGIONAL HEADQUARTERS

OTHER SYSMEX GROUP COMPANIES

  1. Home
  2. Products & Solution
  3. Library
  4. Sysmex Journal International
  5. 2019 Vol.29 No.1
  6. Evaluating the Utility of a Novel Research Use Index in Platelet Aggregation Analysis Featured in an Automated Blood Coagulation Analyzer to Confirm the Effect of Antiplatelet Drugs

Sysmex Journal International

2019Vol.29 No.1

Republished

Evaluating the Utility of a Novel Research Use Index in Platelet Aggregation Analysis Featured in an Automated Blood Coagulation Analyzer to Confirm the Effect of Antiplatelet Drugs

AUTHOR(S)

Tasuku SAKAYORI*1, Yuri WATANABE*1, Keisuke KITANO*1, Yohei MATSUI*2, Daiki KARINO*2, Nobuo ARAI*1 and Yutaka KOMIYAMA*3

*1 Engineering 1, Sysmex Corporation
*2 Engineering 2, Sysmex Corporation
*3 ICH Business Development, Sysmex Corporation
(Current affiliation: Faculty of Health and Medical Sciences, Hokuriku University)

SUMMARY

The main purpose of measuring platelet aggregation is to confirm the effect of antiplatelet drugs. Although the automated blood coagulation analyzers (CS-5100, CS-2500, CS-2400, CS-2100i and CS-2000i) measure platelet aggregation, they are not equipped to confirm the effect of antiplatelet drugs, unlike the semi-automated analyzers currently used in Japan. We have developed platelet aggregation level (PAL), a research use only (RUO) scoring system to use the current platelet aggregation testing method to confirm the effect of antiplatelet drugs.

The values of ADP-induced PAL (APAL), obtained when ADP was used as an agonist, and collagen-induced PAL (CPAL), obtained when collagen was used as an agonist, decreased in a concentration-dependent manner in cangrelor (P2Y12 inhibitor) and aspirin-treated samples, respectively. In addition, the values significantly decreased before and after the addition. APAL and CPAL showed a significantly close relationship, with a correlation coefficient of ≥ 0.90, with the existing natural standard range-II (NSR-II) system.

We suggested that the automated blood coagulation analyzer can test the effect of antiplatelet drugs as a dedicated semi-automated analyzer. Thus, our innovation is expected to assist institutions that cannot afford the new instrument due to cost and space limitations by enabling easy testing using an automated blood coagulation analyzer.

KEY WORDS

Platelet Aggregation, Light Transmission Aggregometry, Antiplatelet Drug, PAL (Platelet Aggregation Level)

NOTE(S)

This article is based on current regulatory requirements in Japan. (as of Nov. 2018)
The specifications, performances and functions described here may be different depending on the regions or the countries due to the regulatory affairs, legal matters or local guidelines. For more details, please contact your regional affiliates or distributors.
This article is translated and republished from the Sysmex Journal Web Vol.19 No.2, 2018. (Japanese)